Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"

Clinical Pharmacology & TherapeuticsEarly View Reply Response to “What is the Current Clinical Impact of the CYP2C:TG Haplotype?” Pablo Zubiaur, Corresponding Author Pablo Zubiaur [email protected] orcid.org/0000-0002-6150-4320 Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain Correspondence: Pablo Zubiaur ([email protected]) and Andrea Gaedigk ([email protected])Search for more papers by this authorJ. Steven Leeder, J. Steven Leeder orcid.org/0000-0001-6688-0504 Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USASearch for more papers by this authorFrancisco Abad-Santos, Francisco Abad-Santos orcid.org/0000-0002-6519-8885 Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this authorAndrea Gaedigk, Corresponding Author Andrea Gaedigk [email protected] orcid.org/0000-0001-6968-1893 Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA Correspondence: Pablo Zubiaur ([email protected]) and Andrea Gaedigk ([email protected])Search for more papers by this author Pablo Zubiaur, Corresponding Author Pablo Zubiaur [email protected] orcid.org/0000-0002-6150-4320 Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain Correspondence: Pablo Zubiaur ([email protected]) and Andrea Gaedigk ([email protected])Search for more papers by this authorJ. Steven Leeder, J. Steven Leeder orcid.org/0000-0001-6688-0504 Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USASearch for more papers by this authorFrancisco Abad-Santos, Francisco Abad-Santos orcid.org/0000-0002-6519-8885 Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, SpainSearch for more papers by this authorAndrea Gaedigk, Corresponding Author Andrea Gaedigk [email protected] orcid.org/0000-0001-6968-1893 Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA Correspondence: Pablo Zubiaur ([email protected]) and Andrea Gaedigk ([email protected])Search for more papers by this author First published: 16 November 2023 https://doi.org/10.1002/cpt.3093Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Bråten, L.S., Ingelman-Sundberg, M., Jukic, M.M., Molden, E. & Kringen, M.K. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population. Clin. Transl. Sci. 15, 2135–2145 (2022). 2Bråten, L.S. et al. A novel CYP2C-haplotype associated with ultrarapid metabolism of escitalopram. Clin. Pharmacol. Ther. 110, 786–793 (2021). 3Zubiaur, P. & Gaedigk, A. CYP2C18: the orphan in the CYP2C family. Pharmacogenomics 23, 913–916 (2022). 4Leeder, J.S. et al. Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver. Clin. Pharmacol. Ther. 50, 24–32 (2022). 5Stancil, S.L., Nolte, W., Pearce, R.E., Staggs, V.S. & Leeder, J.S. The impact of age and genetics on naltrexone biotransformation. Clin. Pharmacol. Ther. 50, 168–173 (2022). Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation